Program
balstilimab
Also written as “Balstilimab”, “AGEN2034” and “Balstilimab + Zalifrelimab”.
Its studies are mostly in Uterine Cervical Neoplasms · Colorectal Neoplasms · Prostatic Neoplasms · Neoplasms · Hemangiosarcoma, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Agenus | 81 open or running | phase 3since Jun 4, 2021 | Mar 27, 2017 | Sep 2027phase 2 · NCT05608044 |
| ImmunoGenesis | 11 open or running | phase 2since Jan 9, 2025 | Jan 9, 2025 | Oct 2027phase 2 · NCT06782555 |
| Rottapharm Biotech | 11 open or running | phase 2since Jan 20, 2022 | Jan 20, 2022 | Dec 2026phase 2 · NCT05205330 |
Also a collaborator on its studies: Betta Pharmaceuticals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 27, 2017First study: phase 2 study in Uterine Cervical NeoplasmsNew to AgenusAgenus · NCT03104699 · 211 enrolled · United States, Australia, Belgium and more
- Jan 19, 2018Phase 2 study in Uterine Cervical NeoplasmsAgenus · NCT03495882 · 175 enrolled · United States, Australia, Brazil and more
- Mar 19, 2019Phase 2 study in Uterine Cervical NeoplasmsAgenus · NCT03894215 · 211 enrolled · United States, Brazil, Mexico and more
- Sep 18, 2019Phase 1 study in NeoplasmsAgenus · NCT04156100 · 19 enrolled · United States
- Oct 16, 2020Phase 2 study in HemangiosarcomaAgenus · NCT04607200
- Jun 4, 2021Phase 3 study in Uterine Cervical NeoplasmsAgenus · NCT04943627 · United States, Armenia
- Aug 27, 2021Phase 2 study in Uterine Cervical NeoplasmsAgenus · NCT05033132 · China
- Jan 20, 2022Rottapharm Biotech's first study: phase 2 study in Colorectal NeoplasmsNew to Rottapharm BiotechRottapharm Biotech · NCT05205330 · 107 enrolled · Italy
- Nov 1, 2022Phase 2 study in Colorectal NeoplasmsAgenus · NCT05608044 · 234 enrolled · United States, Belgium, Brazil and more
- Jan 9, 2025ImmunoGenesis's first study: phase 2 study in Prostatic NeoplasmsNew to ImmunoGenesisImmunoGenesis · NCT06782555 · 71 enrolled · United States
Ahead
- Dec 2026Primary completion: phase 2 study in Colorectal NeoplasmsRottapharm Biotech · NCT05205330
- Sep 2027Primary completion: phase 2 study in Colorectal NeoplasmsAgenus · NCT05608044
- Oct 2027Primary completion: phase 2 study in Prostatic NeoplasmsImmunoGenesis · NCT06782555
TargetBeta
“A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1; PDCD1) protein, ”NCIt, by rule
“Programmed cell death protein 1 antagonist”ChEMBL 37, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06782555Prostatic Neoplasms · United States | 2 | Active, not recruiting | ImmunoGenesis | Oct 2027 | 71 |
| NCT05608044Colorectal Neoplasms · United States, Belgium, Brazil and more | 2 | Active, not recruiting | Agenus | Sep 2027 | 234 |
| NCT05205330Colorectal Neoplasms · Italy | 2 | Active, not recruiting | Rottapharm Biotech | Dec 2026 | 107 |
| NCT05033132Uterine Cervical Neoplasms · China | 2 | Withdrawn | Agenus | Dec 30, 2024 | 0 |
| NCT04943627Uterine Cervical Neoplasms · United States, Armenia | 3 | Withdrawn | Agenus | Oct 22, 2021 | 0 |
| NCT04607200Hemangiosarcoma | 2 | Withdrawn | Agenus | Sep 13, 2021 | 0 |
| NCT04156100Neoplasms · United States | 1 | Terminated | Agenus | Apr 8, 2021 | 19 |
| NCT03894215Uterine Cervical Neoplasms · United States, Brazil, Mexico and more | 2 | Terminated | Agenus | Mar 26, 2025 | 211 |
| NCT03495882Uterine Cervical Neoplasms · United States, Australia, Brazil and more | 2 | Completed | Agenus | Jul 15, 2022 | 175 |
| NCT03104699Uterine Cervical Neoplasms · United States, Australia, Belgium and more | 2 | Completed | Agenus | Jun 15, 2022 | 211 |
How it is read
Names in the registry
- “Balstilimab”, 4 entries
- “AGEN2034”, 4 entries
- “Balstilimab + Zalifrelimab”, 1 entry
- “Balstilimab (BAL)”, 1 entry
- “AGEN1223 and balstilimab”, 1 entry
Conditions, from the studies’ own filings
- Uterine Cervical Neoplasms, 5 studies
- Colorectal Neoplasms, 2 studies
- Prostatic Neoplasms, 1 study
- Neoplasms, 1 study
- Hemangiosarcoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.